This study aims to explore symptoms for Black women with heart failure using surveys and interviews. Black women have not been included in the majority of heart failure research. It is important that Black women have a voice and the ability to share their symptom experience. The goal of this research is to study clusters of heart failure symptoms in Black women to eventually improve symptom education, monitoring, and treatments.
Patients with Alzheimer Disease and patients with Heart failure (and a control group free from both the previous mentioned conditions) will be evaluated with cardiac and neuropsychological assessments, in order to investigate the relationship between the two conditions. 8 follow up visits will be repeated yearly, for 8 years.
This study is being done to find out if we can better monitor subjects with heart failure with the use of a wearable device (called SimpleSense garment) that can monitor multiple factors of heart failure that affect the body such as heart rate, activity, heart rhythm, and respiratory rate. Participants will wear the SimpleSense garment for 90 days for at least 12 hours daily. Participation in the study will include two research clinic visits and 2 phone calls over 4 months. Participants will be compensated for time and travel.
Risks of this study include loss of confidentiality, blood draw and skin irritation from wearing the garment.
We will recruit patients with atrial fibrillation during office visits, inpatient admission, and at time of elective direct current cardioversions.
We will record 15 minutes of ECG data and data from the Mindmics earbuds during office visit or prior to and after cardioversion.
We will use the recorded data to formulate algorithms to discern atrial fibrillation from normal sinus rhythm.
The Revivent TC System study is being conducted to test an investigational device that can repair a Left Ventricular Aneurysm without the use of a heart-lung machine, or opening the chest/heart chamber. The device works by placing a tuck in the heart where there is scar, which has the effect of shortening the distance across the heart and decreasing the tension, or stress, on the working heart muscle. The device consists of several implants, called anchors. The anchors are placed during a surgery in which your doctors will access your heart by placing a guide wire through a vein in your neck into your heart and also through an incision in your chest wall between your ribs on your left side. The anchors will help reshape your heart muscle by tucking in the scarred area. It is expected that the total study duration will be approximately 6 years, consisting of 1 year of patient enrollment and 5 years of patient follow-up.
Prospective Phase 3b multinational, multicenter, double-blind, placebo-controlled,
randomized withdrawal, parallel group study that includes Screening and 12 weeks Run-in Phase (all subjects will have patiromer initiated and RAASi medications, including mineralocorticoid receptor antagonist (MRA), optimized) and a randomized withdrawal Blinded Treatment Phase.
REDUCE study is researching the safety and effectiveness of GORE® CARDIOFORM Septal Occluder (GSO ) device in closing the patent foramen ovale (PFO) in patients who have a PFO and had a stroke of unknown origin (cryptogenic stroke). This device has been approved by the United States Food and Drug Administration for this indication.
A PFO is a common opening in the wall (septum) between the two upper chambers (the right and left atria) of the heart. In most cases, this opening closes around the time of birth. If the opening remains after birth, it can allow the blood to mix in the two upper chambers of the heart.
In most people, leaving the opening untreated has no negative consequences. However, in some patients who have had a stroke of unknown origin (cryptogenic stroke), the presence of a PFO may increase the risk of having another stroke if the opening is left untreated.
This is a prospective, multicenter clinical trial for individuals presenting to the Emergency Department with suspicion of acute heart failure. A blood sample collected will be used to compare the standard of care BNP test used at the local site to the investigational assay from Beckman Coulter (sponsor).
The diagnosis and treatment of patients at each site will use an FDA-cleared BNP or NT-proBNP assay under the site's standard of care and NOT the investigational assay.
This is a multicenter cross-sectional pilot analysis of objective and subjective neurocognitive deficits (NCD) and genetics in the Adults with Congenital Heart Disease (ACHD) population ages 18-30 years with moderate and severe complexity of congenital heart disease (CHD).
The expectation is that studying NCD in ACHD will help to guide access to resources and appropriate medical care for these patients. This research should facilitate the use of targeted interventions in the ACHD population with NCD to enhance both long term quality of care and quality of life (QOL).